David T Ting, MD

Dr. Ting is a physician-scientist and leader in cancer innovation at Mass General Brigham Cancer Institute, widely recognized for pioneering contributions to cancer genomics, RNA biology, and the development of novel diagnostic approaches. A renowned cancer biologist and bioengineer, he integrates cutting-edge laboratory discovery with clinical care, with a particular focus on gastrointestinal cancers, to improve cancer diagnosis, treatment selection, and disease monitoring. His research focuses on RNA expression patterns and tumor heterogeneity, with the goal of identifying clinically actionable biomarkers and novel therapeutic strategies. His lab discovered aberrant expression of non-coding repeat RNAs that mimic viral responses and appear to influence the tumor microenvironment and metastasis and has helped pioneer single-cell and circulating tumor cell analyses to advance blood-based biomarkers.

Dr. Ting earned his BS in chemical engineering and biology from MIT and his MD, magna cum laude, from Harvard Medical School through the Harvard–MIT Health Sciences and Technology program. He completed residency at Massachusetts General Hospital and fellowship training in Hematology/Oncology through the combined Brigham and Women’s Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute program, with postdoctoral training at Mass General. His honors include the AACR NextGen Star Award, ASCI Young Physician-Scientist Award, and the Burroughs Wellcome Fund Career Award for Medical Scientists.

Education & Training

• Fellowship: Dana Farber Cancer Institute*, Medical Oncology, 2011
• Residency: Massachusetts General Hospital, Internal Medicine, 2007
• Medical Education: Harvard Medical School, 2004

Board Certifications

• Medical Oncology, American Board of Internal Medicine

Languages Spoken

• English

Age Group Treated

• Adults